#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Necrotising enterocolitis neonatal Lung adenocarcinoma Cardiomyopathy Cardiac failure acute Acute myeloid leukaemia recurrent Arterial disorder Rhabdomyosarcoma Spinal cord injury cervical Neonatal alloimmune thrombocytopenia Acute graft versus host disease Infertility female Crohn's disease Hodgkin's disease Mitochondrial encephalomyopathy Adrenocortical carcinoma More trials…

    Learn about Rare Diseases

    Haemophilia B without inhibitors – Trials in Disease Leiomyosarcoma recurrent – Treatment Isodicentric chromosome 15 syndrome – Basic Information Prader-Willi syndrome Pemphigus – Life with Disease Pituitary-dependent Cushing’s syndrome – Treatment Alport’s syndrome – Trials in Disease Factor IX deficiency – Treatment Stevens-Johnson syndrome – Basic Information Undifferentiated sarcoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bms-986315 VANDETANIB Microcrystalline Cellulose CC-97540 Copper (64Cu) Chloride Calcium Lactate Gluconate Fexofenadine Hydrochloride Pyruvic Acid Cart 19/22 T Cells Tipranavir Clozapine JX10 Mebeverine Hydrochloride Betibeglogene Autotemcel Ruxolitinib Viltolarsen ZODASIRAN Gozetotide Mometasone Furoate Cefotaxime More therapies…

    Learn about Your Condition

    Dry mouth Arteriospasm coronary Tachypnoea Renal cell carcinoma stage IV HER2 protein overexpression Factor IX deficiency Cardiac valve disease Stress urinary incontinence Rubella Chronic hepatitis B Psychotic behaviour Oxygen saturation Desmoplastic melanoma Penile squamous cell carcinoma Thrombolysis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • A study to evaluate the safety and effectiveness of dalbavancin in patients with erysipelas or limited cellulitis being treated at home.

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Dalbavancin
    Austria

  • Study on the effectiveness of dexamethasone and chloroprocaine in extending the effects of spinal anesthesia for patients undergoing knee arthroscopy

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Chloroprocaine Hydrochloride
    • Dexamethasone Phosphate
    • Sodium Chloride
    France

  • A study comparing vedolizumab, filgotinib, ustekinumab, and infliximab to maintain remission in patients with ulcerative colitis

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Filgotinib
    • Vedolizumab
    • Infliximab
    France

  • A study of mezigdomide, carfilzomib, and dexamethasone in patients with relapsed or refractory multiple myeloma.

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Mezigdomide
    • Carfilzomib
    • Dexamethasone
    France

  • Comparison of standard dosing and blood level monitoring of abiraterone acetate for patients with metastatic castration-resistant prostate cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Abiraterone Acetate
    The Netherlands

  • Using fludeoxyglucose (18F) in PET/CT imaging to diagnose and monitor cardiovascular device infections

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Device related infection
    Investigated Drugs:
    • Fludeoxyglucose (18F)
    Spain
Previous Page
1 … 725 726 727 728 729 … 1,656
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!